SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult ...
Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60 ...
Company becomes preferred manufacturing partner for Brazilian and international pharmaceutical companies launching or expanding in Latin America's largest healthcare market ROUND ROCK, Texas, March 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results